Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
- PMID: 33809722
- PMCID: PMC8002338
- DOI: 10.3390/ijms22063031
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
Abstract
Medullary thyroid carcinoma (MTC) is a tumor deriving from the thyroid C cells. Vandetanib (VAN) and cabozantinib (CAB) are two tyrosine kinase inhibitors targeting REarranged during Transfection (RET) and other kinase receptors and are approved for the treatment of advanced MTC. We aim to compare the in vitro and in vivo anti-tumor activity of VAN and CAB in MTC. The effects of VAN and CAB on viability, cell cycle, and apoptosis of TT and MZ-CRC-1 cells are evaluated in vitro using an MTT assay, DNA flow cytometry with propidium iodide, and Annexin V-FITC/propidium iodide staining, respectively. In vivo, the anti-angiogenic potential of VAN and CAB is evaluated in Tg(fli1a:EGFP)y1 transgenic fluorescent zebrafish embryos by analyzing the effects on the physiological development of the sub-intestinal vein plexus and the tumor-induced angiogenesis after TT and MZ-CRC-1 xenotransplantation. VAN and CAB exert comparable effects on TT and MZ-CRC-1 viability inhibition and cell cycle perturbation, and stimulated apoptosis with a prominent effect by VAN in MZ-CRC-1 and CAB in TT cells. Regarding zebrafish, both drugs inhibit angiogenesis in a dose-dependent manner, in particular CAB shows a more potent anti-angiogenic activity than VAN. To conclude, although VAN and CAB show comparable antiproliferative effects in MTC, the anti-angiogenic activity of CAB appears to be more relevant.
Keywords: angiogenesis; cabozantinib; medullary thyroid carcinoma (MTC); tumor xenograft; tyrosine kinase inhibitors (TKIs); vandetanib; zebrafish.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures







Similar articles
-
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.Cancer Biol Ther. 2017 Jul 3;18(7):473-483. doi: 10.1080/15384047.2017.1323594. Epub 2017 May 5. Cancer Biol Ther. 2017. PMID: 28475408 Free PMC article.
-
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.Thyroid. 2021 Mar;31(3):459-469. doi: 10.1089/thy.2020.0206. Epub 2020 Sep 23. Thyroid. 2021. PMID: 32781914
-
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.Health Technol Assess. 2019 Feb;23(8):1-144. doi: 10.3310/hta23080. Health Technol Assess. 2019. PMID: 30821231 Free PMC article.
-
Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.Arch Endocrinol Metab. 2017 Jul-Aug;61(4):398-402. doi: 10.1590/2359-3997000000267. Epub 2017 Jun 26. Arch Endocrinol Metab. 2017. PMID: 28658345 Free PMC article. Review.
-
Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.J Clin Endocrinol Metab. 2013 Apr;98(4):1529-40. doi: 10.1210/jc.2012-3671. Epub 2013 Mar 18. J Clin Endocrinol Metab. 2013. PMID: 23509102 Free PMC article.
Cited by
-
An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.Int J Mol Sci. 2024 Aug 6;25(16):8568. doi: 10.3390/ijms25168568. Int J Mol Sci. 2024. PMID: 39201255 Free PMC article. Review.
-
Identification of side effects of COVID-19 drug candidates on embryogenesis using an integrated zebrafish screening platform.Sci Rep. 2023 Oct 9;13(1):17037. doi: 10.1038/s41598-023-43911-3. Sci Rep. 2023. PMID: 37813860 Free PMC article.
-
One Host-Multiple Applications: Zebrafish (Danio rerio) as Promising Model for Studying Human Cancers and Pathogenic Diseases.Int J Mol Sci. 2022 Sep 6;23(18):10255. doi: 10.3390/ijms231810255. Int J Mol Sci. 2022. PMID: 36142160 Free PMC article. Review.
-
Metastatic medullary thyroid carcinoma: a new way forward.Endocr Relat Cancer. 2022 May 31;29(7):R85-R103. doi: 10.1530/ERC-21-0368. Endocr Relat Cancer. 2022. PMID: 35521769 Free PMC article. Review.
-
How Tumors Affect Hemodynamics: A Diffusion Study on the Zebrafish Transplantable Model of Medullary Thyroid Carcinoma by Selective Plane Illumination Microscopy.Int J Mol Sci. 2024 Dec 13;25(24):13392. doi: 10.3390/ijms252413392. Int J Mol Sci. 2024. PMID: 39769158 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous